Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01007097 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 426
- Enrollment target
NCT01007097 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 426 participants.
The verdict
NCT01007097, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 426 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of multiple doses of TAK-875, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
Interventions
- DRUG TAK-875
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01007097
The ClinicalTrials.gov registry entry for NCT01007097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-875 is the first listed.
NCT01007097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01007097 about?
NCT01007097 is a clinical study titled "Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to determine the safety and efficacy of multiple doses of TAK-875, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT01007097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 426 participants. The study started on 2009-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01007097?
The interventions under investigation include: TAK-875 (DRUG).
Who is sponsoring clinical trial NCT01007097?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.